SUBSCRIBE TO OUR RSS
Biggest Market Movers
The Burrill Report
January 13, 2012
[Please login to post comments]
Comparative Effectiveness Studies of Cancer Drugs Is Costly
NCI researchers say high cost of some drugs makes it difficult to assess them against cheaper treatments.
Pfizer and AstraZeneca Team with Cancer Research UK to Advance Personalized Medicine
Researchers will have access to pharmas’ drug libraries, testing several drugs at same time in lung cancer trial.
Privately Held Life Sciences Companies Raise $1.5B so Far in April
Biotechs rake in $188 million in series B cash in short week before Easter.
The Rise in Drug Spending and What It Means
Podcast: April 21, 2014
Scripps Initiative Nabs J&J Innovation as First Collaborator
Program aims to translate promising early-stage research into clinical candidates.
HHS Secretary Sebelius Resigns
Biotech IPOs Cool Amid Market Jitters
As public market enthusiasm wavers, companies going public face tougher terms.
Mallinckrodt To Buy Questcor for $5.6 Billion
Deal adds high-value specialty drug to pharma’s growing pipeline.
Study Highlights Opportunities to Reduce Spending on Costly Specialty Drugs
New report says payers could benefit by transitioning specialty medications from the medical to the pharmacy benefit.
Personalizing Cancer Therapies with a Mouse
Podcast: April 14, 2014
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER